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Essentials
• We determined which bleeding symptoms from bleeding assessment tools (BATs) best predict von Willebrand disease (VWD).
• Many symptoms were strongly related to a VWD diagnosis, notably joint bleeding, postsurgical bleeding, and heavy period bleeding.
• Some symptoms were better predictors of VWD than others; therefore, adding relative weightings to each bleeding symptom may improve future BATs.
• There is value in assessing multiple bleeding symptoms when eliciting a bleeding history.
| INTRODUCTION
The diagnosis of bleeding disorders such as von Willebrand disease (VWD) can be a challenge for physicians. Mild bleeding events are common in individuals without bleeding disorders and the reporting and interpretation of hemorrhagic events is subjective. As a result, there has been significant focus over the past decade on the development of bleeding assessment tools (BATs) to aid in the quantification of bleeding symptoms and standardize bleeding histories. 1 BATs are questionnaires that score a range of bleeding symptoms based on their severity and generate an overall quantitative bleeding score. The Vicenza Bleeding Questionnaire (BQ), was developed in 2005, followed by the MCMDM-1VWD BQ in 2006, and subsequently its condensed form in 2008; the latter reduced the administration time from 40 to 10 minutes. 1, 2 In 2009, the Pediatric Bleeding Questionnaire (PBQ) added consideration of pediatric-specific bleeding symptoms to the existing Condensed MCMDM-1VWD BQ. 3 Bleeding assessment tools are an important part of the diagnostic workup of VWD because they can help prioritize laboratory testing as well as standardize communication of bleeding histories among clinicians. However, BATs have been criticized for being time consuming and for their limited utility outside of research settings. 5 In response, efforts have been made to make BATs more accessible to patients through development of a self-administered BAT and to expand their use beyond VWD to other bleeding disorders. 1, 6, 7 Several recent reviews discuss their value and limitations. 1, 5, 6, [8] [9] [10] The study and optimization of BATs clearly remains an active and evolving field of research.
Since BATs have been available for more than a decade, significant amounts of data have been collected from their use. In this study, we used our legacy data to determine which questions from BATs are the strongest predictors of a VWD diagnosis. We believe that the identification of these questions may serve to streamline BATs in future revisions and optimize their clinical utility.
| PATIENTS AND METHODS

| Legacy data
The legacy data contain bleeding scores, demographic data, and VWD-relevant laboratory data collected from 1167 Canadian subjects for prior use in 9 studies ranging over 10 years. 2, 6, [11] [12] [13] [14] [15] [16] We chose to exclude subjects who were <12 years of age, and thus a total of 927 patients were included. We chose to exclude the younger patients because their presenting symptoms differ and they have not had the opportunity to experience some of the hemorrhagic challenges (eg, menarche) assessed by BATs. Data were collected via expert administration prior to a laboratory-defined VWD diagnosis using the Condensed MCMDM-1VWD BQ (n = 730), ISTH-BAT (n = 56), PBQ (n = 141). Questions on the BATs relate to different bleeding symptoms (eg, epistaxis and cutaneous bleeding), and each symptom is scored on the basis of its severity.
Both the PBQ and ISTH-BAT contain an Other Bleeding symptom category (which includes umbilical stump bleeding, cephalohematoma, cheek hematoma during breast/bottle feeding, postcircumcision and postvenipuncture bleeding). Given that these symptoms are specific to infants, we did not include this category in our analysis. Table 1 , adapted from Bowman and James, 8 displays a comparison of the 3 BATs and bleeding symptom categories. The white row is for the Pediatric Bleeding Questionnaire, the medium gray row is for the Condensed MCMDM-1VWD Bleeding Questionnaire, and the dark gray row is for the ISTH-BAT. Scores were considered clinically significant if they were of 2 or greater, as outlined in bold. *Consultation only: the patient sought medical evaluation and was either referred to a specialist or offered detailed laboratory investigation.
| Laboratory definition of VWD and controls
D&C, dilation and curettage; PBAC, Pictorial Blood Loss Assessment Chart; rFVIIa, recombinant factor VIIa.
additional requirement for a heightened ristocetin-induced platelet aggregation response. For simplicity, all patients with type 2 VWD were combined into 1 group for analysis. Type 3 VWD is diagnosed on the basis of VWF:Ag and/or VWF:RCo < 0.05 U/mL and factor VIII < 0.10 U/mL.
Most controls were recruited from waiting rooms of primary or tertiary outpatient clinics after answering "no" to screening questions that included whether they had been diagnosed with a bleeding disorder or experienced a problem with bleeding or bruising.
Other studies recruited healthy subjects from local advertisements.
| Statistical analysis
Analysis of the association between different bleeding symptoms and VWD diagnosis was performed using multivariable logistic regression with backward elimination. 18 
| RESULTS
A total of 927 individuals were included in the analysis, of whom 783
were healthy controls. Sixteen percent (144/927) of the subjects were patients with VWD, with more than two-thirds having type 1 VWD (99/144). The mean age was 40 years (range, 12-90 years), with 15% (n = 139) of the subjects aged <18 years. Approximately twothirds of the participants were women (613/927). The frequency of subjects with clinically significant scores in each of the bleeding symptom categories as well as abnormal total bleeding scores is reported in Table 2 . Please see Table 3 for relevant laboratory values.
VWD patients most commonly had clinically significant scores in menorrhagia (85% of women; 88/104) and epistaxis (42%; 60/144).
Clinically significant scores in muscle hematoma (8%; 12/144) and
central nervous system (CNS) bleeding (1%; 2/144) were found to be least common.
The number of categories of bleeding symptoms reported by the individual had a major impact on odds ratio (OR) for a VWD diagnosis ( 
| DISCUSSION
The goal of our study was to use our legacy data to determine which bleeding symptoms assessed by presently circulating BATs are most predictive of a laboratory-defined VWD diagnosis. As noted in a recent publication by Rimmer and Houston, 19 were found not to significantly increase the odds of a VWD diagnosis, which was not surprising given their low frequency in both the case and control populations.
We found that the odds of a VWD diagnosis were higher when subjects had significant scores in an increasing number of bleeding symptom categories. In an analysis of patients with type 1 VWD and healthy controls, Rodeghiero et al 23 found that having >2 hemorrhagic symptoms, regardless of severity, was the minimum criterion useful to generate a discriminatory bleeding history (specificity, 99.5%; sensitivity, 64.3%). Our finding suggests that, although most of the bleeding symptoms on BATs were found to be significant predictors, there is value in assessing multiple bleeding symptoms when eliciting a bleeding history.
We also found that being of male sex increased the odds of diagnosis in all analyses. It is likely that bleeding symptoms in men are more of a red flag to both clinicians and patients than in women, leading to faster presentation and diagnosis. It is suggested that 15% of women with heavy menstrual bleeding have an underlying inherited TA B L E 4 Odds of VWD diagnosis with stepwise increase in number of bleeding symptoms reported by each subject F I G U R E 1 Association between bleeding symptoms and VWD diagnosis using multivariable logistic regression with backward elimination. The number of subjects with clinically significant scores in each category is listed in parentheses. For each bleeding symptom, the graph reports the odds ratio and its 95% confidence interval. Significance was set at P < 0.05. Having clinically significant bleeding scores for the symptoms of CNS bleeding and muscle hematoma did not significantly increase the odds of a VWD diagnosis. The Hosmer and Lemeshow test of the goodness of fit suggests the model is a good fit to the data as P = 0.13. The Cox and Snell R 2 was 0.378. The unit for age is increasing decades of years. Female sex was set as the reference category. Please note that the x-axis is not to scale. CNS, given barriers such as lack of understanding regarding the difference between normal and abnormal bleeding and social stigma. 24 Menorrhagia was one of the most predictive symptoms of VWD in all regression models, highlighting the importance of screening women with unexplained menorrhagia for underlying bleeding disorders.
Our study has several limitations. First, the frequency of significant scores for some of the symptoms (namely, muscle hematoma and CNS bleeding) was low, which may mean our analysis of these symptoms was underpowered. It is possible that no significant association with VWD was found for CNS bleeding and muscle hematoma due to a lack of statistical power. However, the clinical importance of these symptoms is undisputable, as they are relatively rare in the general population and raise a red flag for further hemostatic evaluation.
Second, our findings may not be generalizable to all clinical scenarios, as the distribution of patients with VWD in our study is more heavily weighted to type 3 VWD than what is typically seen in practice. This may explain our finding that hemarthrosis was the most significant predictor of VWD in our "all subjects" analysis. Therefore, in the design of future BATs, our results from analysis of only patients with type 1 VWD may be most useful to highlight important symptoms experienced by patients presenting for the first time with bleeding, where a diagnosis of type 1 VWD is more likely. An additional limitation is the lack of replication in the development of our prediction model, which we were unable to perform given our limited case population. Finally, it is critical to highlight that we excluded patients from our study that were aged <12 years, which is an important caveat for interpretation of our results. Given the age restriction, our results predictably shift away from some of the symptoms that are more common triggers for evaluation of a possible mild bleeding disorder in children (eg, recurrent epistaxis, excessive bruising) and toward symptoms seen only in an older age cohort (eg, menorrhagia, postpartum hemorrhage). Our findings relate exclusively to a population of adolescents and adults.
Our study found that most of the bleeding symptoms assessed by
BATs are statistically significant predictors of a laboratory-confirmed VWD diagnosis; however, certain bleeding symptoms may have greater predictive value than others. A recent study by Garcia et al 25 proposed similar conclusions. The authors investigated which ISTH-BAT bleeding symptom subscores contributed the most to the total bleeding score of the ISTH-BAT in patients with type 1 VWD. The authors found that all ISTH-BAT bleeding symptoms were correlated with a diagnosis of type 1 VWD, but some contributed more significantly than others. 25 Future BAT revisions may benefit from the addition of relative weighting for each bleeding symptom to accommodate for this observed variability in contribution of each bleeding symptom to a VWD diagnosis. Our data also suggest that such weightings may be optimized by adjusting them for patient demographics, as the symptoms most predictive of VWD changed when our analysis was divided by age and sex.
Recent research has focused on expanding the use of BATs from tertiary to primary care settings, as well as into the hands of patients in the form a self-BAT. 6, 8 When used outside of the tertiary care setting, there is an understandable tendency to want to reduce the length. 2, 5 We found that nearly all bleeding symptoms evaluated on BATs held their own significance or were rare symptoms that were clinically important. Therefore, removing symptoms to shorten BAT length may compromise efficacy. Our finding of a significant increase in the odds of VWD with a stepwise increase in number of significant bleeding symptom scores further supports evaluation of multiple bleeding symptoms, as represented on BATs.
In conclusion, BATs serve as an important tool to elicit a comprehensive and objective bleeding history to identify patients who may benefit from further hemostatic testing. However, despite their strengths, there may be room for further optimization of these scores, such as the addition of a weighting system to incorporate the differential value of bleeding symptoms in predicting VWD.
F I G U R E 2 Association between bleeding symptoms and type 1 VWD using multivariable logistic regression with backward elimination. The number of subjects with clinically significant scores in each category is listed in parentheses. Having clinically significant scores for the symptoms of CNS bleeding, GI bleeding, and muscle hematoma did not significantly increase the odds of a type 1 VWD diagnosis. The Hosmer and Lemeshow test of the goodness of fit suggests the model is a good fit to the data as P = 0.43. The Cox and Snell R 2 was 0.278. The unit for age is increasing decades of years. Female sex was set as the reference category. Please note that the x-axis is not to scale. CNS, 
